• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Depression is Two to Three Times Greater in Rheumatoid Arthritis Patients Than in the General Population According to This Report

Posted on: Friday, 22 September 2006, 09:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c42489) has announced the addition of the new report from Datamonitor "Stakeholder Insight: Rheumatoid Arthritis - Biologics Battle Up the Treatment Algorithm" to their offering.

Rheumatoid arthritis is a debilitating and life-long disease that is estimated to affect approximately 5 million people in the seven major markets. The launch of anti-TNF products over six years ago and more recent novel target biologic therapies have added significantly to the treatment options, but have resulted in a crowded market for moderate to severe patients.

Scope of this title:

This title gives a disease overview including epidemiology, physician estimated diagnosis rates and severity split, including mild to severe and early active disease

It provides a breakdown of treatment trends in the following markets: US, Japan, France, Germany, Italy, Spain and the UK. PCPs and rheumatologists were surveyed to capture the treatment of the ranging severities with traditional NSAIDs, COX-2s, traditional and biologic DMARDs. A comparative brand assessment was carried out on the key attributes of Enbrel, Remicade, Humira, Orencia, Rituxan/MabThera, Kineret and methotrexate.

Report Highlights Include:

Inclusion of relevant early active RA patients in clinical studies will assist timely approval in this indication, increasing the patient base for any RA product. Definition of 'early' RA requires a balance between the physician ideal of less than 12 months, giving the best patient response, and capturing a substantial proportion of the market.

Physicians estimate nine months from disease onset to diagnosis. 25% of RA patients are estimated to be severe, and take an average of four months before the first DMARD is prescribed, being methotrexate in 60% of physicians. It can be 18-23 months before a severe patient is likely to use a biologic.

Anti-TNF therapy is expected to continue to dominate the first-line biologic use. Humira is perceived to be the most effective in terms of disease modification, indicating a very positive future status for this brand, but Remicade and Kineret could lose the brand battle if perception on certain attributes doesnt improve.

Reasons to order your copy:

Use estimated treatment class patient numbers to forecast product use across the seven major markets

Exploit physician perceptions of key brands on clinical and market attributes, to differentiate products in the crowded rheumatoid arthritis market

Understand differential treatment in niche populations such as severe and early active rheumatoid arthritis

Products Mentioned Include:

Enbrel (etanercept)

Remicade (infliximab)

Humira (adalimumab)

Kineret (anakinra)

Orencia (abatacept)

Rituxan/MabThera (rituximab)

Key Topics Covered Include:

What is rheumatoid arthritis (RA)?

How is it treated?

Coverage of the Stakeholder Insight Survey

Country level "treatment trees"

Country treatment trees

Epidemiology and patient segmentation

Definition of the disease

Epidemiology of rheumatoid arthritis

Key patient segmentations

Disease severity shows an even split among mild and moderate disease, with fewer severe patients

Depression is two to three times greater in RA patients than in the general population

Other co-morbidities include additional autoimmune diseases and stomach ulcers

Diagnosis and treatment options

Presentation and diagnosis lower than in previous surveys

Prescribing trends

NSAID prescribing trends

Brand assessment

Improving treatment outcomes

For more information visit http://www.researchandmarkets.com/reports/c42489

Source: Datamonitor

Source: Business Wire

More News in this Category